xIPOmeter
Tempus
Tempus es una empresa tecnológica que promueve la medicina de precisión a través de conocimientos basados en datos. La plataforma de la empresa utiliza inteligencia artificial y aprendizaje automático para analizar datos clínicos y moleculares, ayudando a investigadores y médicos a tomar decisiones más informadas en la atención al paciente. El trabajo pionero de Tempus en el análisis de datos y la genómica está reconfigurando el enfoque del diagnóstico y el tratamiento de las enfermedades, especialmente el cáncer.
Gráfico NewsHeat
- Semana
- Mes
- Año
- Noticias de prensa
- Noticias corporativas
Los datos del gráfico anterior se basan en datos derivados de nuestro modelo de cálculo XP patentado y pueden modificarse, ajustarse y actualizarse sin previo aviso.
Valoración de empresas
- Valoración
- Precio de las acciones
- Financiación acumulada
Los datos de los cuadros y gráficos se basan en datos de fuentes públicas y, aunque hacemos todo lo posible por recopilarlos, es posible que no coincidan con los datos reales del emisor.
*** - Para ver los datos, conéctese a su cuenta o cree una nueva.
Noticias relacionadas con Tempus177
TempusTempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions - Tempus
Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the company has signed agreements for in-network provider status with Blue Cross Blue Shield (BCBS) of Illinois, Blue Shield of Ca...
Tempushttps://www.tempus.com/news/tempus-now-an-in-network-provider-for-blue-cross-blue-shield-illinois-blue-shield-california-and-more/TempusTempus Announces Four Abstracts Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium - Tempus
Tempus, a leader in artificial intelligence and precision medicine, today announced four abstracts were accepted for presentation at the 2024 San Antonio Breast Cancer Symposium, which convenes from December 10-13, in San Antonio, Texas. “Presenting our l...
Tempushttps://www.tempus.com/news/pr/tempus-announces-four-abstracts-accepted-for-presentation-at-the-2024-san-antonio-breast-cancer-symposium/TempusTempus to Participate in the Piper Sandler 36th Annual Healthcare Conference - Tempus
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, held in New York, New York...
Tempushttps://www.tempus.com/news/pr/tempus-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference/TempusTempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR® - Tempus
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the collaboration with Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of...
Tempushttps://www.tempus.com/news/pr/tempus-molecular-profiling-integration-now-available-through-flatirons-oncoemr/TempusTempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care - Tempus
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with adva...
Tempushttps://www.tempus.com/news/pr/tempus-publishes-study-highlighting-benefits-of-concurrent-rna-and-dna-sequencing-in-advanced-cancer-care/
Ver más (172)Inversores8
New Enterprise Associates
Revolution
T. Rowe Price
Baillie Gifford
Novo Holdings
Franklin Templeton
Google
Franklin Templeton Investments